HER2-NEGATIVE BREAST CANCER
Clinical trials for HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Personalized drug attack on breast cancer before surgery
Disease control CompletedThis study tested if adding a new drug targeted to a tumor's specific genetic changes before surgery could slow cancer growth better than standard hormone therapy alone. It involved 19 people with a common type of breast cancer (ER-positive, HER2-negative). The goal was to see if…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Disease control
Last updated Apr 01, 2026 23:11 UTC
-
New test could unlock precision treatment for tough breast cancers
Disease control CompletedThis study tested whether a specific lab test, called the RAD51-foci score, could predict which patients with advanced HER2-negative breast cancer would benefit most from the drug olaparib. It involved 65 patients, some with known genetic mutations and some without, to see if the…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC